Areas covered: This manuscript contains a detailed discussion of the mechanism of action, the clinical trial development program as well as a review of the benefits and risks of this novel agent. In addition, practical considerations for the use of the agent are also described. Expert commentary...
The mechanism of action of emicizumab causes interference with some commonly used haemostasis tests including the APTT and its associated one﹕tage APTT‐based clotting assays. Chromogenic assays may also be affected but this is dependent on the particular constituents of the reagents. Chromogenic ...
Although the mechanism of action does not directly affect or replace VWF function, emicizumab may be an effective prophylaxis alternative to FVIII/VWF concentrate in patients with concomitant severe HA and VWD.Kristin T. AnsteattBleeding & Clotting Disorders Institute, Dills Family Foundation Center ...
We find that emicizumab binds FX much stronger than FIX (K d =0.05M vs. 5M, t 1/2 =20 s vs. 1 s) with profound consequences on the avidity of the ternary complex, which is dominated by FXs binding properties and a hand-off mechanism from FX to FIX. Moreover, formation and ...